Literature DB >> 31776739

Preliminary study of real-time three-dimensional contrast-enhanced ultrasound of sentinel lymph nodes in breast cancer.

Ziyue Hu1, Xueqing Cheng1, Juan Li2, Jingzhen Jiang1, Zirui Jiang3, Hui Li4, Tingting Li1, Zhenqi Zhang1, Bo Tan1, Man Lu5.   

Abstract

PURPOSE: To investigate the clinical value of real-time three-dimensional contrast-enhanced ultrasound (3D-CEUS) in the detection of sentinel lymph nodes (SLNs) and drainage lymphatics in breast cancer patients.
METHOD: The prospective study was performed in women with pathology-confirmed T1/2 breast cancer between June 2016 and December 2017 who underwent sentinel lymph node biopsy and 3D-CEUS. The number, size, location, enhancement pattern of SLNs, and the lymphatic drainage patterns were reviewed. The routes, location of SLNs, and lymph channels (LCs) on the surface were marked. All patients underwent blue dye-guided sentinel lymph node biopsy (SLNB) finally.
RESULTS: According to the postoperative pathology findings and the blue dye staining of the lymphatic drainage routes, there are six patterns of lymphatic drainage routes and the coincidence rate of the 3D-CEUS was 97.4%; the sensitivity, specificity, positive predictive value, negative predictive value, the LN detection rate, and the correct diagnosis rate of the 3D-CEUS were 75%, 93.0%, 81.8%, 89.9%, 95.3%, and 87.7%, respectively.
CONCLUSION: 3D-CEUS is a new feasible and useful approach to detect the SLNs and LCs. 3D-CEUS can accurately localize the LCs and SLNs and estimate the presence of metastatic lymph nodes. KEY POINTS: • The three-dimensional contrast-enhanced ultrasound can detect the sentinel lymph nodes. • The three-dimensional contrast-enhanced ultrasound can show the stereo direction of sentinel lymph nodes and lymph drainage routes. • The three-dimensional contrast-enhanced ultrasound can accurately localize the LCs and SLNs and estimate the presence of metastatic lymph nodes.

Entities:  

Keywords:  Breast cancer; Contrast media; Sentinel lymph node; Ultrasonography

Mesh:

Substances:

Year:  2019        PMID: 31776739     DOI: 10.1007/s00330-019-06494-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  6 in total

1.  The value of preoperative sentinel lymph node contrast-enhanced ultrasound for breast cancer: a large, multicenter trial.

Authors:  Juan Li; Hui Li; Ling Guan; Yun Lu; Weiwei Zhan; Yijie Dong; Peng Gu; Jian Liu; Wen Cheng; Ziyue Na; Lina Tang; Zhongshi Du; Lichun Yang; Saiping Hai; Chen Yang; Qingqiu Zheng; Yuhua Zhang; Shan Wang; Fang Li; Jing Fu; Man Lu
Journal:  BMC Cancer       Date:  2022-04-26       Impact factor: 4.638

2.  The value of contrast-enhanced ultrasound enhancement patterns for the diagnosis of sentinel lymph node status in breast cancer: systematic review and meta-analysis.

Authors:  Zihan Niu; Mengsu Xiao; Li Ma; Jing Qin; Wenbo Li; Jing Zhang; Qingli Zhu; Yuxin Jiang
Journal:  Quant Imaging Med Surg       Date:  2022-02

Review 3.  Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment Modulation of Breast Cancer.

Authors:  Ioana Boca Bene; Sorin M Dudea; Anca I Ciurea
Journal:  J Pers Med       Date:  2021-01-30

4.  Preoperative evaluation and influencing factors of sentinel lymph node detection for early breast cancer with contrast-enhanced ultrasonography: What matters.

Authors:  Shihui Ma; Yuguang Xu; Feihai Ling
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

5.  Prediction of Metastasis in the Axillary Lymph Nodes of Patients With Breast Cancer: A Radiomics Method Based on Contrast-Enhanced Computed Tomography.

Authors:  Chunmei Yang; Jing Dong; Ziyi Liu; Qingxi Guo; Yue Nie; Deqing Huang; Na Qin; Jian Shu
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

6.  Optimal Selection of Imaging Examination for Lymph Node Detection of Breast Cancer With Different Molecular Subtypes.

Authors:  Mingjie Zheng; Yue Huang; Jinghui Peng; Yiqin Xia; Yangyang Cui; Xu Han; Shui Wang; Hui Xie
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.